Efficacy and safety of perampanel monotherapy in Chinese patients with focal‐onset seizures: A single‐center, prospective, real‐world observational study
Epilepsia Open · 2023
DOI: 10.1002/epi4.12823 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Epilepsia Open, 2023. Verfasst von Haiyan Ma und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Functional Neurosurgery, Nanjing Brain Hospital affiliated to Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: East Asian People, Anticonvulsants. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Nanjing Medical Science and Technology Development Project.
Abstract (Originalsprache)
Objective
Efficacy and safety of perampanel monotherapy for treating focal‐onset seizures (FOS) has been barely studied in China. This observational study aimed to evaluate the efficacy and safety of perampanel monotherapy in treating Chinese patients with FOS.
Methods
This single‐center, prospective, real‐world observational study enrolled patients aged ≥4 years with FOS who visited the Epilepsy Out‐Patient Clinic of Nanjing Brain Hospital affiliated to Nanjing Medical University from January 2020 to December 2021. All patients were treated with perampanel monotherapy. Seizure‐freedom rates after 6 and 12 months of treatment were calculated. Adverse events (AEs) were recorded.
Results
Seventy patients with FOS were enrolled. The mean maintenance perampanel dose was 4.64 ± 1.55 mg/day. The 6‐ and 12‐month retention rates of perampanel monotherapy were 78.6% (55/70) and 70.0% (49/70), respectively. The 6‐ and 12‐month seizure‐freedom rates were 69.84% (44/63) and 65.08% (41/63), respectively. Patients with focal to bilateral tonic–clonic seizures had significantly higher 6‐month and numerically higher 12‐month seizure freedom rates than patients with focal impaired awareness seizures ( P = 0.046 and P = 0.204, respectively). Twenty‐six (37.1%) patients experienced treatment‐emergent AEs, and the most common AE was dizziness. Four (5.7%) patients withdrew from the study due to AEs. No new safety concern was observed. Significance This is the first prospective study on the efficacy and safety of perampanel monotherapy in treating Chinese patients with FOS, and perampanel monotherapy was effective and safe in treating Chinese patients aged ≥4 years with FOS up to 12 months. More multicenter, real‐world studies with large sample sizes and longer follow‐ups are needed to further evaluate the long‐term efficacy and safety of perampanel monotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Functional Neurosurgery, Nanjing Brain Hospital affiliated to Nanjing Medical University, Nanjing, China.
Förderung
- Nanjing Medical Science and Technology Development Project
Zitieren
APA
Ma, H., Zhu, H., Chen, F., Yang, Y., Qu, X., Xu, H., Yang, L., & Zhang, R. (2023). Efficacy and safety of perampanel monotherapy in Chinese patients with focal‐onset seizures: A single‐center, prospective, real‐world observational study. Epilepsia Open. https://doi.org/10.1002/epi4.12823
Vancouver
Ma H, Zhu H, Chen F, Yang Y, Qu X, Xu H, et al. Efficacy and safety of perampanel monotherapy in Chinese patients with focal‐onset seizures: A single‐center, prospective, real‐world observational study. Epilepsia Open. 2023. doi:10.1002/epi4.12823
BibTeX
@article{Ma2023,
author = {Ma, Haiyan and Zhu, Haitao and Chen, Fangqing and Yang, Yiqing and Qu, Xuefeng and Xu, Honghao and Yang, Lu and Zhang, Rui},
title = {Efficacy and safety of perampanel monotherapy in Chinese patients with focal‐onset seizures: A single‐center, prospective, real‐world observational study},
journal = {Epilepsia Open},
year = {2023},
doi = {10.1002/epi4.12823}
}
EUVIMED